I M Hons1, M A Storr, K Mackie, B Lutz, Q J Pittman, G M Mawe, K A Sharkey. 1. Department of Physiology & Pharmacology, Hotchkiss Brain Institute and Snyder Institute of Infection, Immunity and Inflammation, University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND: The enteric nervous system (ENS) possesses extensive synaptic connections which integrate information and provide appropriate outputs to coordinate the activity of the gastrointestinal tract. The regulation of enteric synapses is not well understood. Cannabinoid (CB)(1) receptors inhibit the release of acetylcholine (ACh) in the ENS, but their role in the synapse is not understood. We tested the hypothesis that enteric CB(1) receptors provide inhibitory control of excitatory neurotransmission in the ENS. METHODS: Intracellular microelectrode recordings were obtained from mouse myenteric plexus neurons. Interganglionic fibers were stimulated with a concentric stimulating electrode to elicit synaptic events on to the recorded neuron. Differences between spontaneous and evoked fast synaptic transmission was examined within preparations from CB(1) deficient mice (CB(1)(-/-)) and wild-type (WT) littermate controls. KEY RESULTS: Cannabinoid receptors were colocalized on terminals expressing the vesicular ACh transporter and the synaptic protein synaptotagmin. A greater proportion of CB(1)(-/-) neurons received spontaneous fast excitatory postsynaptic potentials than neurons from WT preparations. The CB(1) agonist WIN55,212 depressed WT synapses without any effect on CB(1)(-/-) synapses. Synaptic activity in response to depolarization was markedly enhanced at CB(1)(-/-) synapses and after treatment with a CB(1) antagonist in WT preparations. Activity-dependent liberation of a retrograde purine messenger was demonstrated to facilitate synaptic transmission in CB(1)(-/-) mice. CONCLUSIONS & INFERENCES: Cannabinoid receptors inhibit transmitter release at enteric synapses and depress synaptic strength basally and in an activity-dependent manner. These actions help explain accelerated intestinal transit observed in the absence of CB(1) receptors.
BACKGROUND: The enteric nervous system (ENS) possesses extensive synaptic connections which integrate information and provide appropriate outputs to coordinate the activity of the gastrointestinal tract. The regulation of enteric synapses is not well understood. Cannabinoid (CB)(1) receptors inhibit the release of acetylcholine (ACh) in the ENS, but their role in the synapse is not understood. We tested the hypothesis that enteric CB(1) receptors provide inhibitory control of excitatory neurotransmission in the ENS. METHODS: Intracellular microelectrode recordings were obtained from mouse myenteric plexus neurons. Interganglionic fibers were stimulated with a concentric stimulating electrode to elicit synaptic events on to the recorded neuron. Differences between spontaneous and evoked fast synaptic transmission was examined within preparations from CB(1) deficientmice (CB(1)(-/-)) and wild-type (WT) littermate controls. KEY RESULTS:Cannabinoid receptors were colocalized on terminals expressing the vesicular ACh transporter and the synaptic protein synaptotagmin. A greater proportion of CB(1)(-/-) neurons received spontaneous fast excitatory postsynaptic potentials than neurons from WT preparations. The CB(1) agonist WIN55,212 depressed WT synapses without any effect on CB(1)(-/-) synapses. Synaptic activity in response to depolarization was markedly enhanced at CB(1)(-/-) synapses and after treatment with a CB(1) antagonist in WT preparations. Activity-dependent liberation of a retrograde purine messenger was demonstrated to facilitate synaptic transmission in CB(1)(-/-) mice. CONCLUSIONS & INFERENCES: Cannabinoid receptors inhibit transmitter release at enteric synapses and depress synaptic strength basally and in an activity-dependent manner. These actions help explain accelerated intestinal transit observed in the absence of CB(1) receptors.
Authors: Ian M Hons; Joshua E Burda; John R Grider; Gary M Mawe; Keith A Sharkey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-02-12 Impact factor: 4.052
Authors: Maria Antonietta Casu; Anna Porcella; Stefania Ruiu; Pierluigi Saba; Giorgio Marchese; Mauro Antonio Maria Carai; Roberta Reali; Gian Luigi Gessa; Luca Pani Journal: Eur J Pharmacol Date: 2003-01-10 Impact factor: 4.432
Authors: M Bashashati; Y Nasser; C M Keenan; W Ho; F Piscitelli; M Nalli; K Mackie; M A Storr; V Di Marzo; K A Sharkey Journal: Br J Pharmacol Date: 2015-04-23 Impact factor: 8.739
Authors: C M Keenan; M A Storr; G A Thakur; J T Wood; J Wager-Miller; A Straiker; M R Eno; S P Nikas; M Bashashati; H Hu; K Mackie; A Makriyannis; K A Sharkey Journal: Br J Pharmacol Date: 2015-02-27 Impact factor: 8.739
Authors: Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack Journal: Nat Rev Gastroenterol Hepatol Date: 2022-09-27 Impact factor: 73.082
Authors: Jane A Roberts; Mark K Lukewich; Keith A Sharkey; John B Furness; Gary M Mawe; Alan E Lomax Journal: Curr Opin Pharmacol Date: 2012-10-11 Impact factor: 5.547
Authors: Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer Journal: Trends Pharmacol Sci Date: 2015-03-18 Impact factor: 14.819
Authors: Arthur Lionnet; Matthew A Wade; Anne-Gaëlle Corbillé; Alice Prigent; Sébastien Paillusson; Maddalena Tasselli; Jacques Gonzales; Emilie Durieu; Malvyne Rolli-Derkinderen; Emmanuel Coron; Emilie Duchalais; Michel Neunlist; Michael S Perkinton; Diane P Hanger; Wendy Noble; Pascal Derkinderen Journal: Acta Neuropathol Commun Date: 2018-07-23 Impact factor: 7.801